Message Font: Serif | Sans-Serif
 
No. of Recommendations: 1
http://finance.yahoo.com/news/pipeline-advances-exelixis-223...

Presumably Zachs has it correct. It would seem to me that EXEL's co promotion option is to put a check on the sort of thing that was alleged to happen with Byetta, wherein Lilly shared profits with AMLN, but Lilly was alleged to not have promoted the drug with all zeal, and in fact was producing a competing drug in its own pipeline.

With the right to copromote, EXEL could use its own sales force to sell the drug even if Roche decided to be less than zealous in doing so itself.

Tinker
Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement